PDCD1 and cancer: Accordingly, blocking PD-1/PD-L1 signaling has shown great efficacy in various cancers, however in a large proportion of patients PD-1/PD-L1 blockade shows limited success, highlighting the importance of understanding underlying mechanisms of checkpoint inhibitor blockade as well as defining biomarkers to predict treatment success (39).